investingreview.org logo
事実を把握し、ベストを見つけ、詐欺を避ける
Nothings Found.

New Leaf Venture Partners 13F Holdings Compared: Q3 2022 vs. Q4 2022

Ava Hoppe | 1 May, 2023

Investors are always eager to learn what is happening with their portfolio, and it is no different for shareholders of New Leaf Venture Partners. With the release of the recent 13F holdings comparison report for Q3 2022 versus Q4 2022, a few things stand out.

First, the overall value of assets held by New Leaf declined from $270,841,000 in Q3 2022 to $106,308,000 in Q4 2022, representing a decrease of over 60%. This drop-in value was likely driven by some companies' losses, as indicated by the change percentages.

Second, there were some significant changes in holdings among the different companies. In particular, Rallybio Corporation saw a huge increase in shares, from 2,301,603 to 3,301,603, but the change percentage was -34.9%. On the other hand, Aravive Inc. had a change percentage of 61.6% with a rise in the number of shares from 946,423 to 946,423.

Below we take a closer look at some of the companies that saw significant changes in holdings according to New Leaf Venture Partners' Q3 2022 vs. Q4 2022 13F Holdings Comparison report.

Rallybio Corporation (RLYB)

With a negative change percentage of -34.9%, Rallybio Corporation saw a massive increase in the number of shares held by New Leaf Venture Partners. The biopharmaceutical company is focused on developing therapies for patients with severe and rare disorders.

Deciphera Pharmaceuticals Inc. (DCPH)

Deciphera Pharmaceuticals Inc., focused on developing cancer therapies, saw a decrease of 11.4% in shares held by New Leaf.

Aravive Inc. (ARAV)

On the other hand, Aravive Inc. had a significant increase of 61.6% in shares held by New Leaf. Aravive is a clinical-stage biopharmaceutical company developing therapies for patients with various cancer types.

X4 Pharmaceuticals Inc. (XFOR)

X4 Pharmaceuticals Inc. saw a decrease of 41.9% in shares held by New Leaf. X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare diseases.

Overall, the Q3 2022 versus Q4 2022 13F holdings comparison report by New Leaf Venture Partners indicates a significant shift in holdings. While some companies saw an increase in shares, others saw a decline, resulting in a decrease in the overall value of the assets held by New Leaf Venture Partners. Nevertheless, investors should remain vigilant and critically evaluate their investment strategies to achieve optimal returns.

多くの人々が詐欺やPonziスキームによってやけどを負っています。だから私たちはあなた、潜在的な投資家を助け、事実を見つけ、最高のものを見つけ、そして詐欺とPonziの計画を避けるためにこのウェブサイトを作成しました。

このWebサイトで提供されるすべての情報は、無保証で、情報提供のみを目的として提供されています。
InvestingReview.orgは投資アドバイスを提供していません。 InvestingReview.orgは投資顧問ではなく、米国または米国以外の規制機関によって承認または提携されていません。


最近検索された企業

注:検索データは第三者によって蓄積され、1日に1回更新されます.

Copyright©2023年InvestingReview.org /すべての権利予約。